Patents Examined by Barry A Chestnut
  • Patent number: 11066712
    Abstract: The present invention provides a method for rapid, highly specific and sensitive detection and quantification of a virus by observing viral substrate binding to its host receptor protein. The invention also provides a method for rapid, highly specific and sensitive detection and quantification of a virus in an individual suspected of being infected with a virus. The invention further provides a test kit for rapid, highly specific and sensitive point-of-care detection of a virus in an individual. The viruses and their host receptor proteins that can rapidly be detected include SARS-CoV-2 and its host receptor protein ACE2. The surprisingly rapid, specific and sensitive method and kit of the invention provide a point-of care test capable of diagnosing individuals suffering from COVID-19 by observation of a color change in the assay, which color change occurs in about five minutes, and which test can be completed by a user in about 60 minutes.
    Type: Grant
    Filed: November 21, 2020
    Date of Patent: July 20, 2021
    Inventors: Bret T. Barnhizer, Jonathan P. Faro
  • Patent number: 11067583
    Abstract: The present invention provides a method of making an antibody by identifying a circulating antibody with activity from a subject comprising i) subjecting biological fluid selected from the group consisting of blood, plasma and serum and combinations thereof from the subject to one or more rounds of affinity chromatography to purify the circulating antibody; ii) optionally further subjecting the circulating antibody to isoelectric focusing to purify the circulating antibody based on charge; iii) testing the purified circulating antibody for activity; iv) digesting the purified circulating antibody from parts i) or ii) to create an antibody fragment; v) subjecting the antibody fragment to mass spectrometry to generate a mass assignment and a deduced amino acid sequence of the antibody fragment; vi) comparing the deduced amino acid sequence with an amino acid sequence of an antibody generated from the subject's B-cells to identify an antibody sequence that matches the deduced amino acid sequence; vii) generating
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: July 20, 2021
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Mohammad Sajadi, Anthony DeVico, George Lewis
  • Patent number: 11059882
    Abstract: Dual variable domain immunoglobulins (DVD Igs) are provided capable of tetravalent binding to bispecific sites of the human immunodeficiency virus (HIV). The DVD Igs may be asymmetric and may have more variable domains on either the light chain or the heavy chain of the Igs. The DVD Igs may have specificity for gp41 and gp120. Therapies are provided using DVD Igs to neutralize HIV viral loads.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: July 13, 2021
    Assignee: Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
    Inventors: Seth Pincus, Ryan Craig
  • Patent number: 11058766
    Abstract: The disclosure relates to vaccination compositions, for example, against human papillomavirus, Zika virus, and flu virus. The disclosure also relates to vectors for producing the virus-like particles and immune complex platforms of the vaccination compositions.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: July 13, 2021
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Hugh Mason, Andrew Diamos, Mary Pardhe, Brandon Favre
  • Patent number: 11052139
    Abstract: Provided herein are recombinant poxviruses that are stable through successive passaging of the recombinant poxviruses. More particularly, the recombinant poxviruses comprise one or more modified nucleic acids encoding MUC1, CEA, and/or TRICOM antigens, wherein the recombinant poxviruses are stable through successive passaging. Also, provided herein are compositions and method related thereto.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: July 6, 2021
    Assignee: Bavarian Nordic A/S
    Inventors: Markus Kalla, Ryan Rountree, Ulrike Dirmeier
  • Patent number: 11052147
    Abstract: Described herein are compositions and pharmaceutical compositions including poxviruses, in particular vaccinia virus such as modified vaccinia Ankara (MVA) virus, a sulfate salt at a concentration between about 5 mM and 300 mM and a buffer, wherein the composition has a pH of between about 6.0 and 8.5. Also described are methods for stabilizing a poxvirus composition by preparing said viral formulation.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: July 6, 2021
    Inventors: Ahmad Shakeb Sediq, Wouter Frank Tonnis, Martinus Anne Hobbe Capelle
  • Patent number: 11052090
    Abstract: Compounds, compositions, and methods of treatment and prevention of HIV, including HIV-1 and HIV-2, Dengue, and Chikungunya infection are disclosed. The compounds are TREM-1 inhibitors. Combinations of these TREM-1 inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, JAK inhibitors, macrophage depleting agents, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV, Dengue, or Chikungunya virus in an infected patient.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: July 6, 2021
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Raymond F. Schinazi, Christina Gavegnano
  • Patent number: 11046773
    Abstract: The present invention relates to bispecific polypeptides that are directed against the cellular receptor CD4 as well as a cellular co-receptor for HIV. Said polypeptides may be used to prevent human cell entry of HIV.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: June 29, 2021
    Assignee: Ablynx N.V.
    Inventors: Hugo Soares, Dominique Schols, Peter Vanlandschoot, Philippe Van Rompaey, Catelijne Stortelers
  • Patent number: 11040223
    Abstract: Certain embodiments are directed to composition for inducing an immune response against xCT that is directed to cancer stem cells expressing xCT.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: June 22, 2021
    Assignee: Agilvax Inc.
    Inventors: Federica Cavallo, Stefania Lanzardo, Laura Conti, John P. O'Rourke, Federica Pericle
  • Patent number: 11040097
    Abstract: The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: June 22, 2021
    Assignee: Takeda Vaccines, Inc.
    Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William Tino
  • Patent number: 11033615
    Abstract: The invention generally relates to a purified inactivated Zika virus (ZIKV), methods for producing the purified inactivated ZIKV, immunogenic compositions and vaccines comprising the purified inactivated ZIKV and methods for the prevention and/or treatment of infection by ZIKV.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: June 15, 2021
    Assignees: The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland, The Research Foundation For The State University of New York Syracuse, New York
    Inventors: Stephen J. Thomas, Timothy Endy, Kenneth H. Eckels, J. Robert Putnak, Richard Jarman, Rafael De La Barrera
  • Patent number: 11033618
    Abstract: The invention relates to compositions including a substance useful as an adjuvant for potentiating an immune response, and methods of using the composition in individuals with infections of tissue within or adjacent to a transformation zone, such as the transformation zone of the cervix or anal canal.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: June 15, 2021
    Inventor: Jenny Colleen McCloskey
  • Patent number: 11027009
    Abstract: Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: June 8, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B. Weiner, Matthew Morrow
  • Patent number: 11022611
    Abstract: Disclosed herein are systems and methods for detecting and diagnosing flaviviral or alphaviral infections in subjects in need thereof. The systems and methods of the disclosure enable rapid testing of small volumes of biological sample with the ability to reliably distinguish between flavival and alphaviral infections and determine whether the viral infection is acute or chronic.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: June 1, 2021
    Assignee: Nirmidas Biotech, Inc.
    Inventors: Joshua T. Robinson, Meijie Tang, Su Zhao, Anna Hsu Pao, Hongjie Dai, Bo Zhang, Jeyarama Subramanian Ananta Narayanan
  • Patent number: 11020497
    Abstract: A rod-shaped plant virus having an interior surface and an exterior surface, and at least one imaging agent that is linked to the interior and/or exterior surface is described. The rod-shaped viruses can be combined into larger spherical nanoparticles. A rod-shaped plant virus or spherical nanoparticles including an imaging agent can be used in a method of generating an image of a tissue region of a subject such as a tumor or atherosclerotic tissue by administering the virus particle to the subject and generating an image of the tissue region of the subject to which the virus particle has been distributed.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: June 1, 2021
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Nicole Steinmetz, Michael Bruckman
  • Patent number: 11014962
    Abstract: The present invention provides a method for manufacturing antibodies or a fragment thereof with reduced levels of antibody reduction related impurities.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: May 25, 2021
    Assignee: UCB BIOPHARMA SRL
    Inventors: Richard Jones, Jonathan Symmons, Saskia Hocking
  • Patent number: 11015205
    Abstract: The present invention relates to a method for production of an oligomeric protein in eukaryotic cells by co-expression of two fusion proteins in eukaryotic cells comprising a protein-S-Tag fusion protein, wherein the protein is an antigen or an antibody, and a S-protein-tail piece (tp) fusion protein. Furthermore the present invention relates to an oligomeric protein comprising at least a protein-S-Tag fusion protein and a S-protein-tail piece (tp) fusion protein, wherein the protein of the protein-S-Tag fusion protein is an antigen or an antibody, and the use in vaccines.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: May 25, 2021
    Assignee: Leibniz-Institut für Pflanzengenetik und Kulturpflanzenforschung (IPK)
    Inventors: Hoang Phan, Udo Conrad, Thuong Thi Ho
  • Patent number: 11008380
    Abstract: The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: May 18, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kalpit A. Vora, Kara S. Cox, Aimin Tang, Zhifeng Chen, Daniel DiStefano, Lan Zhang, Hua-Poo Su
  • Patent number: 10988779
    Abstract: The present disclosure relates to viral delivery of RNA utilizing self-cleaving ribozymes and applications of such, including but not limited to CRISPR-Cas related applications.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: April 27, 2021
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Arnold Park, Benhur Lee, Ruth Watkinson
  • Patent number: 10987418
    Abstract: The invention relates to a polypeptide carrier for presenting a target polypeptide, and use thereof. In particular, the invention relates to a nucleic acid molecule, comprising a nucleotide sequence encoding a polypeptide carrier, and being used for insertion of a nucleotide sequence encoding a target polypeptide. In addition, the invention further relates to a recombinant protein comprising the polypeptide carrier and a target polypeptide. Furthermore, the invention further relates to use of the nucleic acid molecule and the recombinant protein. In addition, the invention further relates to a vaccine or a pharmaceutical composition useful for preventing, alleviating or treating HBV infection or a disease associated with HBV infection (e.g., hepatitis B), comprising a recombinant protein comprising the polypeptide carrier of the invention and an epitope from HBV.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: April 27, 2021
    Assignees: XIAMEN UNIVERSITY, YANG SHENG TANG COMPANY, LTD.
    Inventors: Tianying Zhang, Quan Yuan, Xueran Guo, Minxi Wei, Xiaozhen Kang, Jun Zhang, Ningshao Xia